IBD Journal Club:
Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD
Guidelines
ACG Clinical Guidelines: Management of Crohn's Disease in Adults.
Lichtenstein GR, et al. Am J Gastroenterol. 2018;113(4):481-517.
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.
Torres J, et al. J Crohns Colitis. 2020;14(1):4-22.
ACG Clinical Guideline: Ulcerative Colitis in Adults.
Rubin DT, et al. Am J Gastroenterol. 2019;114(3):384-413.
AGA Clinical Practice Guideline on the Management of Moderate to Severe Ulcerative Colitis.
Feuerstein JD, et al. Gastroenterology. 2020;158(5):1450-1461.
ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.
Farraye F, et al. Am J Gastroenterol. 2017;112(2):241-258.
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.
Feuerstein JD, et al. Gastroenterology. 2017;153(3):827-834.
Patient Resources
American College of Gastroenterology
American Gastroenterological Association
Crohn’s and Colitis Foundation
European Crohn’s and Colitis Organisation
National Institute of Diabetes and Digestive and Kidney Diseases
Suggested Readings
Approach to the management of recently diagnosed inflammatory bowel disease patients: a user's guide for adult and pediatric gastroenterologists.
Agrawal M, et al. Gastroenterology. 2021;161(1):47-65.
STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD.
Turner D, et al. Gastroenterology. 2021;160(5):1570-1583.
A treat-to-target update in ulcerative colitis: a systematic review.
Ungaro R, et al. Am J Gastroenterol. 2019;114(6):874-883.
From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting.
Mumolo MG, et al. World J Gastroenterol. 2018;24(33):3681-3694.
The role of laboratory tests in Crohn’s disease.
Cappello M, Morreale GC. Clin Med Insights Gastroenterol. 2016;9:51-62.
Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis.
Sands BE, et al. N Engl J Med. 2019; 381(13):1215-1226.
Comparison of real-world treatment outcomes with vedolizumab versus infliximab in biologic-naive patients with inflammatory bowel disease.
Patel H, et al. Crohn's Colitis 360. 2019;1(2):otz022.
Prediction of outcome of treatment of acute severe ulcerative colitis using principal component analysis and artificial intelligence.
Ghoshal UC, et al. JGH Open. 2020;4(5):889-897.
P025 Ozanimod efficacy, safety, and histology in patients with moderate-to-severe ulcerative colitis during induction in the phase 3 True North study.
Sandborn W, et al. Am J Gastroenterol. 2020;115(suppl 1):S6-S7.
FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions.
US Food and Drug Administration. 2021.
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Colombel JF, et al. Gut. 2017;66(5):839-851.
Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2/3 studies.
Sandborn WJ, et al. Inflamm Bowel Dis. 2021;27(7):994-1007.
Relevant Resources
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
Got it? Treat it!
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
The Emerging Role of the Diabetologist
Key Issues Impacting OB/GYN Practice
An Interactive Experience Highlighting Recent Clinical Advances
Hot Topics in HBV, HCV, and NASH
Emerging Concepts in Patient Management
Building Your Understanding to Combat a Growing Problem
Why It Matters in OB/GYN Practice Today
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
The PCP’s Role in HCV Elimination
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
An Interactive Learning Experience
A Focus on Clinical Evidence and Guideline Recommendations
A Multidisciplinary Online Mini-Curriculum
